The Effect and Safety Assessment of Metformin and DLBS3233 (A Bioactive Fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on Improving Metabolic Parameters in Women with Polycystic Ovary Syndrome

References

• Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261. doi:10.4103/jhrs.JHRS_95_18
   PubMedGoogle Scholar
• Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet. 2019;12:249. doi:10.2147/TACG.S200341
   PubMed Web of Science ®Google Scholar
• Neven ACH, Laven J, Teede HJ, Boyle JA. A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. In: Seminars in Reproductive Medicine. Thieme Medical Publishers; 2018.
   Google Scholar
• Deshpande PS, Gupta AS. Causes and prevalence of factors causing infertility in a public health facility. J Hum Reprod Sci. 2019;12(4):287. doi:10.4103/jhrs.JHRS_140_18
   PubMedGoogle Scholar
• Group TEA-SPCW. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reprod. 2008;23(3):462–477. doi:10.1093/humrep/dem426
   PubMed Web of Science ®Google Scholar
• Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–175.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. doi:10.1210/er.2011-1034
   PubMed Web of Science ®Google Scholar
• Dahan MH, Reaven G. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome. Endocrine. 2019;64(3):685–689. doi:10.1007/s12020-019-01899-9
   PubMed Web of Science ®Google Scholar
• Torchen LC. Cardiometabolic risk in PCOS: more than a reproductive disorder. Curr Diab Rep. 2017;17(12):137. doi:10.1007/s11892-017-0956-2
   PubMed Web of Science ®Google Scholar
• LeRoith D, Taylor SI, Olefsky JM. Diabetes Mellitus: A Fundamental and Clinical Text. Lippincott Williams & Wilkins; 2004.
   Google Scholar
• Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5–12. doi:10.1007/s11154-012-9229-1
   PubMed Web of Science ®Google Scholar
• Soni A, Singla S, Goyal S. Polycystic ovary syndrome: pathogenesis, treatment and secondary associated diseases. J Drug Deliv Therap. 2018;8(5):107–112. doi:10.22270/jddt.v8i5.1892
   Google Scholar
• Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. doi:10.3390/ijms23084110
   PubMed Web of Science ®Google Scholar
• Morgante G, Massaro M, Di Sabatino A, Cappelli V, De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol. 2018;34(1):4–9. doi:10.1080/09513590.2017.1370644
   PubMed Web of Science ®Google Scholar
• Song R. Mechanism of metformin: a tale of two sites. Diabetes Care. 2016;39(2):187–189. doi:10.2337/dci15-0013
   PubMed Web of Science ®Google Scholar
• Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898–1906. doi:10.1007/s00125-013-2991-0
   PubMed Web of Science ®Google Scholar
• Agius L, Ford BE, Chachra SS. The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective. Int J Mol Sci. 2020;21(9):3240. doi:10.3390/ijms21093240
   PubMed Web of Science ®Google Scholar
• Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK, Wu T. Mechanism of glucose‐lowering by metformin in type 2 diabetes: role of bile acids. Diabetes Obes Metab. 2020;22(2):141–148. doi:10.1111/dom.13869
   PubMed Web of Science ®Google Scholar
• Altintas KZ, Dilbaz B, Cirik DA, et al. The incidence of metabolic syndrome in adolescents with different phenotypes of PCOS. Ginekol Pol. 2017;88(6):289–295. doi:10.5603/GP.a2017.0055
   PubMed Web of Science ®Google Scholar
• McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. doi:10.1007/s00125-015-3844-9
   PubMed Web of Science ®Google Scholar
• Fatima M, Sadeeqa S, Nazir SUR. Metformin and its gastrointestinal problems: a review. Biomed Res. 2018;29(11). doi:10.4066/biomedicalresearch.40-18-526
   Google Scholar
• Heaf J. Metformin in chronic kidney disease: time for a rethink. Peritoneal Dial Int. 2014;34(4):353–357. doi:10.3747/pdi.2013.00344
   PubMed Web of Science ®Google Scholar
• Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac JD, Ekinci EI. Metformin: time to review its role and safety in chronic kidney disease. Med J Austr. 2019;211(1):37–42. doi:10.5694/mja2.50239
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? Diabetologia. 2005;48(12):2454–2459. doi:10.1007/s00125-005-0026-1
   PubMed Web of Science ®Google Scholar
• Penzias A, Bendikson K, Butts S; Medicine PCot ASfR. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108(3):426–441. doi:10.1016/j.fertnstert.2017.06.026
   PubMed Web of Science ®Google Scholar
• Goswami PK, Khale A, Ogale S. Natural remedies for polycystic ovarian syndrome (PCOS): a review. Int J Pharm Phytopharmacol Res. 2012;1(6):396–402.
   Google Scholar
• Wiweko B, Susanto CA. The effect of metformin and cinnamon on serum anti-mullerian hormone in women having PCOS: a Double-blind, randomized, controlled trial. J Hum Reprod Sci. 2017;10(1):31. doi:10.4103/jhrs.JHRS_90_16
   PubMedGoogle Scholar
• Nailufar F, Tandrasasmita OM, Tjandrawinata RR. DLBS3233 increases glucose uptake by mediating upregulation of PPARγ and PPARδ expression. Biomed Prevent Nutr. 2011;1(2):71–78. doi:10.1016/j.bionut.2010.12.002
   Google Scholar
• Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR. Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression. Int J Gen Med. 2011;4:345. doi:10.2147/IJGM.S16517
   PubMedGoogle Scholar
• Manaf A, Tjandrawinata RR, Malinda D. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa. Drug Des Devel Ther. 2016;10:1279. doi:10.2147/DDDT.S97568
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48–53. doi:10.1210/jc.2005-1329
   PubMed Web of Science ®Google Scholar
• Takada I, Makishima M. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). Expert Opin Ther Pat. 2020;30(1):1–13. doi:10.1080/13543776.2020.1703952
   PubMed Web of Science ®Google Scholar
• Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Res. 2008;2008:1–9. doi:10.1155/2008/581348
   Web of Science ®Google Scholar
• Al-Snafi A. Medicinal value of Lagerstroemia speciosa: an updated review. Int J Curr Pharm Res. 2019;11(5):18–26. doi:10.22159/ijcpr.2019v11i5.35708
   Google Scholar
• Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol. 2008;60(1):39–51.
   PubMedGoogle Scholar
• Dash R, Lamia SS, Khan F, Sarah H, Islam SS. Phytochemistry and medicinal properties of Lagerstroemia speciosa (Lythraceae) extracts: a review. J Life Sci Rev. 2018;1:1–9.
   Google Scholar